CO6210825A2 - Derivado de heterocicliden-n-(aril)acetamina - Google Patents

Derivado de heterocicliden-n-(aril)acetamina

Info

Publication number
CO6210825A2
CO6210825A2 CO09076006A CO09076006A CO6210825A2 CO 6210825 A2 CO6210825 A2 CO 6210825A2 CO 09076006 A CO09076006 A CO 09076006A CO 09076006 A CO09076006 A CO 09076006A CO 6210825 A2 CO6210825 A2 CO 6210825A2
Authority
CO
Colombia
Prior art keywords
group
substituted
unsubstituted
atom
integer
Prior art date
Application number
CO09076006A
Other languages
English (en)
Inventor
Hideharu Uchida
Shinichi Ogawa
Muneyoshi Makabe
Yoshitaka Maeda
Original Assignee
Mochida Pharmaceutical Co Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39644589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6210825(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mochida Pharmaceutical Co Ltda filed Critical Mochida Pharmaceutical Co Ltda
Publication of CO6210825A2 publication Critical patent/CO6210825A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

1.- Un compuesto, caracterizado porque es representado por la fórmula (I')(en donde k, m, n y p cada uno representan independientemente, un número entero de 0 a 2; j y q representa un número entero de 0 ó 1; R1 representa un grupo seleccionado de un átomo de halógeno, un grupo hidrocarburo sustituido o no sustituido, un grupo heterocíclico sustituido o no sustituido, un grupo alcoxi C1-6 sustituido o no sustituido, un grupo alcoxicarbonilo C1-C6 sustituido o no sustituido, un grupo amino el cual puede ser mono o di-sustituido, un grupo alquilo C1-C6 sustituido o no sustituido, un grupo hidroxilo protegido o no protegido, un grupo carboxilo protegido o no protegido, un grupo carbamoilo el cual puede ser mono o di-sustituido con un grupo alquilo C1-C6 sustituido o no sustituido, un grupo alcanoilo C1-6, un grupo alquiltio C1-6, un grupo alquilsulfinilo C1-6, un grupo alquilsulfonilo C1-6, un grupo sulfamoilo el cual puede ser mono o di-sustituido con un grupo alquilo C1-6 sustituido o no sustituido, un grupo ciano, y un grupo nitro; R2 representa un grupo seleccionado de un átomo de halógeno, un grupo amino sustituido o no sustituido, un grupo hidrocarburo sustituido o no sustituido, un grupo heterocíclico aromático sustituido o no sustituido, y un grupo oxo, o dos R2 germinales o vecinales, pueden estar unidos entre sí para formar un grupo alquileno C2-6, y formar un grupo de anillo ciclo junto con el átomo de carbono al cual los dos R2 están unido o el grupo de anillo ciclo puede formar grupos heterocíclicos no aromáticos que contienen un átomo de oxígeno o un átomo de nitrógeno; X1 representa un átomo de oxígeno, -NR3- (en donde R3 es un átomo de hidrógeno, un grupo hidrocarburo sustituido o no sustituido, un grupo heterocíclico sustituido o no sustituido, o un grupo acilo sustituido o no sustituido), o - S(O)r- (en donde r es un número entero de 0 a 2); X2 representa un grupo metileno, un átomo de oxígeno, -NR3- (en donde R3 es un átomo de hidrógeno, un grupo hidrocarburo sustituido o no sustituido, un grupo heterocíclico sustituido o no sustituido, un grupo acilo sustituido o no sustituido) o -S(O)r- (en donde r es un número entero de 0 a 2); W representa un grupo metileno, un grupo carbonilo o un grupo sulfonilo; ...
CO09076006A 2007-01-24 2009-07-22 Derivado de heterocicliden-n-(aril)acetamina CO6210825A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007014372 2007-01-24

Publications (1)

Publication Number Publication Date
CO6210825A2 true CO6210825A2 (es) 2010-10-20

Family

ID=39644589

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09076006A CO6210825A2 (es) 2007-01-24 2009-07-22 Derivado de heterocicliden-n-(aril)acetamina

Country Status (14)

Country Link
EP (1) EP2128157A4 (es)
JP (1) JPWO2008091021A1 (es)
KR (1) KR20090107068A (es)
CN (1) CN101589038A (es)
AR (1) AR065014A1 (es)
AU (1) AU2008208224A1 (es)
CA (1) CA2676020A1 (es)
CL (1) CL2008000202A1 (es)
CO (1) CO6210825A2 (es)
MX (1) MX2009007954A (es)
PA (1) PA8766901A1 (es)
PE (1) PE20081692A1 (es)
TW (1) TW200902002A (es)
WO (1) WO2008091021A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4754566B2 (ja) 2005-07-22 2011-08-24 持田製薬株式会社 新規なヘテロシクリデンアセトアミド誘導体
NZ571706A (en) * 2006-04-18 2012-06-29 Abbott Lab Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof
JP2011201776A (ja) * 2008-07-23 2011-10-13 Mochida Pharmaceut Co Ltd ヘテロシクリデン−ｎ−（３，４−ジヒドロ−２（１ｈ）−キナゾリノン−５−イル）アセトアミド誘導体
CA2728405A1 (en) * 2008-06-17 2010-01-14 Glenmark Pharmaceuticals, S.A. Chromane derivatives as trpv3 modulators
JP2011201778A (ja) * 2008-07-23 2011-10-13 Mochida Pharmaceut Co Ltd ｐ−置換アリールアセトアミドを有するヘテロシクリデン誘導体
JP2011201777A (ja) * 2008-07-23 2011-10-13 Mochida Pharmaceut Co Ltd 光学活性なヘテロシクリデン−ｎ−アリールアセトアミド誘導体
CN103635458B (zh) 2011-03-25 2016-10-19 艾伯维公司 Trpv1拮抗剂
US8859584B2 (en) 2011-12-19 2014-10-14 Abbvie, Inc. TRPV1 antagonists
US8969325B2 (en) 2011-12-19 2015-03-03 Abbvie Inc. TRPV1 antagonists
US8796328B2 (en) 2012-06-20 2014-08-05 Abbvie Inc. TRPV1 antagonists
CA3150748A1 (en) * 2019-08-23 2021-03-04 Mochida Pharmaceutical Co., Ltd. Method for producing heterocyclidene acetamide derivative
KR102334947B1 (ko) * 2020-04-22 2021-12-06 주식회사 제이맥켐 Trpv1 길항제로서 벤즈이미다졸론계 시남아마이드 유도체 및 이를 유효성분으로 함유하는 통증의 치료 또는 예방용 약학적 조성물
RU2755206C1 (ru) 2020-05-20 2021-09-14 Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) Средство пролонгированного анальгетического действия и лекарственный препарат на его основе

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9309621D0 (en) 1993-05-11 1993-06-23 Wellcome Found Amide derivatives and their therapeutic use
NZ271454A (en) 1993-08-26 1997-07-27 Yamanouchi Pharma Co Ltd Difluoro substituted benzazepine derivatives and pharmaceutical compositions
DE19620170A1 (de) 1996-05-20 1997-11-27 Wolfgang Prof Dr Dr Pfleiderer Nucleosid-Derivate mit photolabilen Schutzgruppen
AR011913A1 (es) 1997-03-06 2000-09-13 Yamano Masaki Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos.
AU1309701A (en) 1999-11-15 2001-05-30 Nissan Chemical Industries Ltd. Hydrazone compounds and pesticides
US6120964A (en) 1999-12-15 2000-09-19 Eastman Kodak Company 2-(1,2-benzisothiazol-3(2H)-ylidene 1,1-dioxide)acetamides negative charge control agents for electrostatographic toners and developers
EP1445253B1 (en) 2001-11-16 2009-08-05 Astellas Pharma Inc. 4,4-difluoro-1, 2, 3, 4-tetrahydro-5h-1-benzazepine derivatives or salts thereof
US7582657B2 (en) * 2001-12-10 2009-09-01 Amgen Inc. Vanilloid receptor ligands and their use in treatments
ATE416168T1 (de) * 2002-02-15 2008-12-15 Glaxo Group Ltd Modulatoren des vanilloidrezeptors
CA2486530A1 (en) * 2002-05-29 2003-12-11 Amgen Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives for the treatment of cell proliferation-related disorders
CA2510471A1 (en) 2002-12-19 2004-07-08 Neurogen Corporation Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators
WO2004069792A2 (en) 2003-02-03 2004-08-19 Janssen Pharmaceutica N.V. Quinoline-derived amide modulators of vanilloid vr1 receptor
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
US7585878B2 (en) 2003-06-12 2009-09-08 Astellas Pharma Inc. Benzamide derivative or salt thereof
GB0319151D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
ATE399782T1 (de) 2003-09-22 2008-07-15 Euro Celtique Sa Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
JP4667384B2 (ja) 2003-10-07 2011-04-13 レノビス， インコーポレイテッド イオンチャネルリガンドとしてのアミド誘導体および薬学的組成物、ならびにこれらを使用する方法
CA2542494A1 (en) * 2003-10-15 2005-05-06 Bayer Healthcare Ag Tetrahydro-naphthalene and urea derivatives
US7037927B2 (en) 2003-10-16 2006-05-02 Abbott Laboratories Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor
WO2005044802A2 (en) 2003-11-08 2005-05-19 Bayer Healthcare Ag Tetrahydro-quinolinylurea derivatives as vrl antagonists
US7553848B2 (en) 2004-01-23 2009-06-30 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2005095329A1 (en) 2004-03-31 2005-10-13 Pfizer Japan Inc. Substituted benzamide compounds as vr1 receptor antagonists
JP4018739B2 (ja) 2004-07-15 2007-12-05 日本たばこ産業株式会社 縮合ベンズアミド化合物及びバニロイド受容体１型（ｖｒ１）活性阻害剤
EP1799661A1 (en) 2004-10-08 2007-06-27 AstraZeneca AB New hydroxymethylbenzothiazoles amides
WO2006058338A2 (en) 2004-11-29 2006-06-01 Janssen Pharmaceutica N.V. 4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor
ES2255848B1 (es) 2004-12-16 2007-07-01 Consejo Superior Investig. Cientificas Derivados de isoquinolina como inhibidores de calpaina.
JP2007014372A (ja) 2005-07-05 2007-01-25 Kariya Mokuzai Kogyo Kk 椅子
JP4754566B2 (ja) * 2005-07-22 2011-08-24 持田製薬株式会社 新規なヘテロシクリデンアセトアミド誘導体

Also Published As

Publication number Publication date
JPWO2008091021A1 (ja) 2010-05-20
MX2009007954A (es) 2009-08-07
CN101589038A (zh) 2009-11-25
PA8766901A1 (es) 2009-06-23
CL2008000202A1 (es) 2009-10-02
TW200902002A (en) 2009-01-16
PE20081692A1 (es) 2008-12-18
EP2128157A1 (en) 2009-12-02
AU2008208224A1 (en) 2008-07-31
KR20090107068A (ko) 2009-10-12
WO2008091021A1 (ja) 2008-07-31
AR065014A1 (es) 2009-05-13
CA2676020A1 (en) 2008-07-31
EP2128157A4 (en) 2010-03-17

Similar Documents

Publication Publication Date Title
CO6210825A2 (es) Derivado de heterocicliden-n-(aril)acetamina
TW200722422A (en) Heterocyclic compound and organic electroluminescent device using the same
AR107377A2 (es) Compuestos derivados de tetrahidroquinolina
EA200870362A1 (ru) Способ получения производных лактамида, новые производные лактамида и препараты, содержащие производные лактамида
AR049646A1 (es) Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
BRPI0516911A (pt) método para a preparação de um composto e composto de anilina
ES2543607T3 (es) Ciertas amidas sustituidas, método de obtención, y método de su uso
ECSP056023A (es) Métodos para aislar la forma cristalina I de la 5-azacitidina
TW200612920A (en) Novel imidazolidine derivatives
TW200602461A (en) Dibenzofuran, dibenzothiophene and fluorene derivatives
ATE431333T1 (de) Amino-propanolderivate
NO20054787D0 (no) Indenderivater som farmasotiske midler
CO6150146A2 (es) Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas su preparacion y su aplicacion en terapeutica
BRPI0615248A2 (pt) derivado tendo atividade agonista de ppar
WO2009010789A3 (en) Pyrimidine derivatives 934
DE602006019732D1 (de) Indolylmaleimidderivate
DK1008592T3 (da) Cykliske amidderivater, som inhiberer cathepsin K
AR053342A1 (es) Quinolonas y naftiridonas 7- maino alquilildenil- heterociclicas
AR053453A1 (es) Derivados de aminoalquil- y amidoalquil-benzopirano substituidos
RS53088B (en) LOW MOLECULAR TRP-P8 ACTIVITY MODULATORS
CU23854B1 (es) Nuevos compuestos heterocíclicos nitrogenados y medicamento antibacteriano que los comprende
AR066604A1 (es) Derivados de arilamida pirimidona, medicamentos que los contienen y usos terapeuticos para prevenir y/o tratar enfermedades neurodegenerativas fundamentalmente.
AR041882A1 (es) Compuestos de imidazopiridina, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR054747A1 (es) Compuestos de indanil-piperazina un procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR054072A1 (es) 3-amino arilpropil indoles como inhibidores de reabsorcion de monoaminas. procesos de obtencion y composiciones farmaceuticas

Legal Events

Date Code Title Description
FA Application withdrawn